Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25263745 | 1.00 | IDO1 (0.34) | IDO1AOC3TACR1LMNASMN1; SMN2 | |
| SCHEMBL25833880 | 0.84 | IDO1 (0.34) | IDO1AOC3TACR1LMNASMN1; SMN2 | |
| SCHEMBL25831720 | 0.83 | AOC3 (0.37) | IDO1AOC3TACR1LMNASMN1; SMN2 | |
| SCHEMBL25305309 | 0.83 | AOC3 (0.37) | IDO1AOC3TACR1LMNASMN1; SMN2 | |
| SCHEMBL25258426 | 0.81 | MAPT (0.38) | AOC3TACR1LMNASMN1; SMN2SLC6A2 | |
| SCHEMBL13232231 | 0.76 | IDO1 (0.41) | IDO1TACR1SMN1; SMN2 | |
| SCHEMBL25262042 | 0.73 | GBA1 (0.35) | AOC3LMNASMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL25831633 | 0.73 | GBA1 (0.35) | AOC3LMNASMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL791863 | 0.73 | IDO1 (0.58) | IDO1TACR1MAPT | |
| SCHEMBL25857978 | 0.72 | ABCB11 (0.39) | IDO1TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | IDO1 917/4885AOC3 3111/4885TACR1 2172/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | IDO1 917/4885AOC3 3111/4885TACR1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.